Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and
Timolol in subjects with open-angel glaucoma or ocular hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.